Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.
Rituximab may be a preferred treatment option vs first-line corticosteroid-sparing agents for patients with pemphigus who are at risk for cardiovascular and metabolic conditions, according to study findings published in JAMA Dermatology.
Pemphigus is a potentially life-threatening autoimmune skin disease, and patients with the condition are more susceptible to death compared with the general population. Proper treatment, particularly with the first-line corticosteroid-sparing agents mycophenolate mofetil (MMF) and azathioprine, has been shown to substantially reduce risk of mortality.
“However, the main challenge in treating pemphigus is to maintain long-term remission with the smallest dose of systemic corticosteroids for the shortest time, aiming to mitigate their life-threatening adverse events,” said the study authors.
Another alternative treatment option, rituximab, a monoclonal chimeric mouse/human antibody directed against CD20-expressing B lymphocytes, has also shown promising efficacy for the condition. Recent research showed that rituximab was superior to MMF in producing sustained complete remission and achieving a lower cumulative dose of corticosteroids, but more patients receiving treatment with rituximab experienced severe adverse events.
“While this study illuminated the safety profile of these drugs, our knowledge about the long-term complications of rituximab, MMF, and azathioprine remains sparse,” said researchers.
They conducted a global population–based retrospective cohort study to further assess the risk of long-term cardiovascular and metabolic outcomes and all-cause mortality in patients with pemphigus managed by rituximab (n = 961; mean [SD] age, 54.8 [16.6] years) compared with those receiving treatment with azathioprine and MMF (n = 961; mean (SD) age, 54.4 [18.2] years).
Eligible patients were enrolled from the Global Collaborative Network of TriNetX platform and underwent propensity score matching to optimize comparability. The primary outcomes examined were risk of myocardial infarction, stroke, peripheral vascular disease, pulmonary embolism, hypertension, hyperlipidemia, type 2 diabetes, obesity, osteoporosis, and avascular bone necrosis.
A total of 1602 participants were included in the analysis, of whom 855 (53.4%) were women and 747 (46.6%) were men.
Compared with those treated with azathioprine/MMF, patients treated with rituximab experienced a lower risk of several cardiovascular and metabolic outcomes:
Risk of pulmonary embolism and avascular necrosis of the bone was shown to be similar between both groups. Moreover, all-cause mortality was comparable between patients in both groups (HR, 0.94; 95% CI, 0.62-1.43; log-rank P = .77). Thirty-seven deaths occurred in the rituximab group compared with 60 in the azathioprine/MMF group.
The use of retrospective data was cited as a potential limitation of the analysis, as well as the lack of clinical data about the immunological and clinical features of the disease, which interfered with investigating the efficacy of treatment.
“Clinicians treating patients with pemphigus should be aware of the study findings,” concluded the study authors. “Rituximab might be considered positively in individuals with cardiovascular and metabolic risk factors, for whom corticosteroid-related adverse events must be avoided.”
Reference
Kridin K, Mruwat N, Ludwig RJ. Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus. JAMA Dermatol. Published online November 30, 2022. doi:10.1001/jamadermatol.2022.5182
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Health Equity and Access Weekly Roundup: May 11, 2024
May 11th 2024This week's topics include frameworks for improving health equity nationwide, addressing social determinants of health, discussing CMS's Medicare rules, investigating breast cancer treatment refusal, and exploring HIV and major depressive disorder in underrepresented groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More